Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
January 17 2023 - 4:05PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that it will
participate in two upcoming investor conferences.
B. Riley Securities’ 3rd Annual Oncology ConferenceWednesday,
January 18, 20237:00AM PT/10:00AM ET
5th Annual Guggenheim Oncology DaysThursday, February 9,
20236:35AM PT/9:35AM ET
Any available webcasts will be posted to the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following a live webcast, a replay will be
available on the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T products for cancer and the potential benefits of AlloCAR T.
Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the Securities and Exchange Commission
(SEC), including without limitation in its Form 8-K filed
on November 29, 2022 and under the “Risk Factors” heading
of its Form 10-Q for the quarter ended September 30, 2022. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Jessica BernsteinSenior Manager, Corporate and Internal
CommunicationsJessica.Bernstein@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2023 to Apr 2024